99 related articles for article (PubMed ID: 17257899)
1. Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice.
Link JM; Rich CM; Korat M; Burrows GG; Offner H; Vandenbark AA
Clin Immunol; 2007 Apr; 123(1):95-104. PubMed ID: 17257899
[TBL] [Abstract][Full Text] [Related]
2. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice.
Vandenbark AA; Rich C; Mooney J; Zamora A; Wang C; Huan J; Fugger L; Offner H; Jones R; Burrows GG
J Immunol; 2003 Jul; 171(1):127-33. PubMed ID: 12816990
[TBL] [Abstract][Full Text] [Related]
3. T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice.
Chou YK; Culbertson N; Rich C; LaTocha D; Buenafe AC; Huan J; Link J; Wands JM; Born WK; Offner H; Bourdette DN; Burrows GG; Vandenbark AA
J Neurosci Res; 2004 Sep; 77(5):670-80. PubMed ID: 15352213
[TBL] [Abstract][Full Text] [Related]
4. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice.
Rich C; Link JM; Zamora A; Jacobsen H; Meza-Romero R; Offner H; Jones R; Burrows GG; Fugger L; Vandenbark AA
Eur J Immunol; 2004 May; 34(5):1251-61. PubMed ID: 15114658
[TBL] [Abstract][Full Text] [Related]
5. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L
Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182
[TBL] [Abstract][Full Text] [Related]
6. Recombinant T cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis: dose effects and involvement of both CD4 and CD8 T cells.
Kumar V; Coulsell E; Ober B; Hubbard G; Sercarz E; Ward ES
J Immunol; 1997 Nov; 159(10):5150-6. PubMed ID: 9366445
[TBL] [Abstract][Full Text] [Related]
7. A novel protective model against experimental allergic encephalomyelitis in mice expressing a transgenic TCR-specific for myelin oligodendrocyte glycoprotein.
Mendel I; Natarajan K; Ben-Nun A; Shevach EM
J Neuroimmunol; 2004 Apr; 149(1-2):10-21. PubMed ID: 15020060
[TBL] [Abstract][Full Text] [Related]
8. A chimeric TCR-beta chain confers increased susceptibility to EAE.
Petersen TR; Lata R; Spittle E; Bäckström BT
Mol Immunol; 2007 Jul; 44(14):3473-81. PubMed ID: 17481734
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Adamus G; Brown L; Andrew S; Meza-Romero R; Burrows GG; Vandenbark AA
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):406-12. PubMed ID: 22167100
[TBL] [Abstract][Full Text] [Related]
10. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch.
Huan J; Subramanian S; Jones R; Rich C; Link J; Mooney J; Bourdette DN; Vandenbark AA; Burrows GG; Offner H
J Immunol; 2004 Apr; 172(7):4556-66. PubMed ID: 15034073
[TBL] [Abstract][Full Text] [Related]
11. Hla-DR2-restricted responses to proteolipid protein 95-116 peptide cause autoimmune encephalitis in transgenic mice.
Kawamura K; Yamamura T; Yokoyama K; Chui DH; Fukui Y; Sasazuki T; Inoko H; David CS; Tabira T
J Clin Invest; 2000 Apr; 105(7):977-84. PubMed ID: 10841661
[TBL] [Abstract][Full Text] [Related]
12. TCR vaccination in aluminum adjuvant protects against autoimmune encephalomyelitis.
Aroeira LS
Clin Immunol; 2006 Jun; 119(3):252-60. PubMed ID: 16503420
[TBL] [Abstract][Full Text] [Related]
13. Soluble egg antigen from Schistosoma japonicum modulates the progression of chronic progressive experimental autoimmune encephalomyelitis via Th2-shift response.
Zheng X; Hu X; Zhou G; Lu Z; Qiu W; Bao J; Dai Y
J Neuroimmunol; 2008 Feb; 194(1-2):107-14. PubMed ID: 18207251
[TBL] [Abstract][Full Text] [Related]
14. Copolymer effects on microglia and T cells in the central nervous system of humanized mice.
Illes Z; Stern JN; Keskin DB; Reddy J; Brosnan CF; Waldner H; Santambrogio L; Kuchroo VK; Strominger JL
Eur J Immunol; 2005 Dec; 35(12):3683-93. PubMed ID: 16259003
[TBL] [Abstract][Full Text] [Related]
15. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF
Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803
[TBL] [Abstract][Full Text] [Related]
16. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis.
Jones MV; Nguyen TT; Deboy CA; Griffin JW; Whartenby KA; Kerr DA; Calabresi PA
J Neuroimmunol; 2008 Aug; 199(1-2):83-93. PubMed ID: 18582952
[TBL] [Abstract][Full Text] [Related]
17. TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes.
Dahan R; Tabul M; Chou YK; Meza-Romero R; Andrew S; Ferro AJ; Burrows GG; Offner H; Vandenbark AA; Reiter Y
Eur J Immunol; 2011 May; 41(5):1465-79. PubMed ID: 21469129
[TBL] [Abstract][Full Text] [Related]
18. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
19. Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Chang JW; Mechling DE; Bächinger HP; Burrows GG
J Biol Chem; 2001 Jun; 276(26):24170-6. PubMed ID: 11319230
[TBL] [Abstract][Full Text] [Related]
20. Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis.
Offner H
J Neurosci Res; 2004 Dec; 78(5):603-24. PubMed ID: 15515048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
